|
Confronting the challenge of antimicrobial resistance
March 11, 2008NIAID describes research efforts aimed at reducing antimicrobial resistance
Drug resistance is making many diseases increasingly difficult--and sometimes impossible--to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. "Extensively drug-resistant tuberculosis and invasive methicillin-resistant Staphylococcus aureus (MRSA) infections are just two recent examples of this problem that pose serious threats to domestic and global health," he adds. In a new report in the Journal of Infectious Diseases, now available online, Dr. Fauci outlines NIAID's commitment to addressing this urgent public health issue.
The innate ability of microbes to evade containment and destruction by drugs through rapid reproduction and genetic mutation is exacerbated by the overuse and misuse of existing antimicrobial drugs, Dr. Fauci and his coauthors note. Other factors contributing to the upswing in drug resistance include a dearth of rapid diagnostic tests that would allow physicians to better gauge whether a given infection is drug-susceptible or drug-resistant, and a paucity of clinical trial data to guide therapeutic strategies.
NIAID is meeting the complex challenge of antimicrobial resistance through a multifaceted research approach that includes partnerships with other federal agencies, academia, industry and non-governmental organizations, the authors report. In fiscal year 2007, NIAID invested more than $800 million to support basic and translational research on antimicrobials, more than $200 million of which was devoted to understanding the causes, consequences and treatments of antimicrobial drug resistance.
Basic research projects under way at NIAID or in NIAID-supported labs across the country include the following:
* Investigations of mechanisms of resistance and how these traits are acquired and passed on by microbes
* Research on factors that contribute to the virulence of pathogens such as MRSA
* Efforts to better understand and ultimately prevent biofilms--slimy coatings made by communities of bacteria that are impervious to the effects of antibiotics
* Creation of computer-based virtual microbial metabolic pathways that allow quick identification of potential drug targets
Facilitating the translation of basic research findings into better diagnostics, new therapies and novel strategies to slow the emergence of antimicrobial resistance is also an area of emphasis for the Institute, write the authors. The following are examples of the many applied and translational research programs supported by NIAID:
* Numerous clinical trials, including is assessing the need for antibiotics in children with acute middle-ear infections; and two trials designed to test off-patent oral antibiotics for treating uncomplicated community-associated MRSA
* Preclinical development of vaccine candidates to prevent staphylococcal infections
* Efforts to improve diagnostics, particularly for healthcare-associated bacterial infections that are already or are likely to become drug-resistant, such as Clostridium difficile, Pseudomonas and Acinetobacter
* DNA sequencing and other genomics resources that aid in discovery of diagnostics and therapeutics
Finally, the authors outline several new and established NIAID partnerships addressing antimicrobial resistance, including
* The Federal Interagency Task Force on Antimicrobial Resistance, co-chaired by NIAID, the Centers for Disease Control and Prevention, and the Food and Drug Administration, which implements an annually updated action plan
* The international Lilly Not-For-Profit Partnership for TB Early Phase Drug Discovery, which integrates the expertise of the pharmaceutical industry with university-based researchers to develop new drugs against TB, including multidrug-resistant and extensively drug-resistant forms of TB
* A collaboration with the Novartis Institute for Tropical Diseases to advance new drugs to treat dengue fever
"With antimicrobial resistance, we face the perpetual challenge of maintaining a favorable balance between microbes and humans," says Dr. Fauci. "The efforts of NIAID and all our partners from the public health, research and pharmaceutical sectors are critical to addressing this challenge and thus keeping us at least one step ahead of our microbial foes."
NIH/National Institute of Allergy and Infectious Diseases
NIAID is meeting the complex challenge of antimicrobial resistance through a multifaceted research approach that includes partnerships with other federal agencies, academia, industry and non-governmental organizations, the authors report. In fiscal year 2007, NIAID invested more than $800 million to support basic and translational research on antimicrobials, more than $200 million of which was devoted to understanding the causes, consequences and treatments of antimicrobial drug resistance.
Basic research projects under way at NIAID or in NIAID-supported labs across the country include the following:
* Investigations of mechanisms of resistance and how these traits are acquired and passed on by microbes
* Research on factors that contribute to the virulence of pathogens such as MRSA
* Efforts to better understand and ultimately prevent biofilms--slimy coatings made by communities of bacteria that are impervious to the effects of antibiotics
* Creation of computer-based virtual microbial metabolic pathways that allow quick identification of potential drug targets
Facilitating the translation of basic research findings into better diagnostics, new therapies and novel strategies to slow the emergence of antimicrobial resistance is also an area of emphasis for the Institute, write the authors. The following are examples of the many applied and translational research programs supported by NIAID:
* Numerous clinical trials, including is assessing the need for antibiotics in children with acute middle-ear infections; and two trials designed to test off-patent oral antibiotics for treating uncomplicated community-associated MRSA
* Preclinical development of vaccine candidates to prevent staphylococcal infections
* Efforts to improve diagnostics, particularly for healthcare-associated bacterial infections that are already or are likely to become drug-resistant, such as Clostridium difficile, Pseudomonas and Acinetobacter
* DNA sequencing and other genomics resources that aid in discovery of diagnostics and therapeutics
Finally, the authors outline several new and established NIAID partnerships addressing antimicrobial resistance, including
* The Federal Interagency Task Force on Antimicrobial Resistance, co-chaired by NIAID, the Centers for Disease Control and Prevention, and the Food and Drug Administration, which implements an annually updated action plan
* The international Lilly Not-For-Profit Partnership for TB Early Phase Drug Discovery, which integrates the expertise of the pharmaceutical industry with university-based researchers to develop new drugs against TB, including multidrug-resistant and extensively drug-resistant forms of TB
* A collaboration with the Novartis Institute for Tropical Diseases to advance new drugs to treat dengue fever
"With antimicrobial resistance, we face the perpetual challenge of maintaining a favorable balance between microbes and humans," says Dr. Fauci. "The efforts of NIAID and all our partners from the public health, research and pharmaceutical sectors are critical to addressing this challenge and thus keeping us at least one step ahead of our microbial foes."
NIH/National Institute of Allergy and Infectious Diseases
Antimicrobial Resistance News and Current Antimicrobial Resistance Events RSSEuropean league-tables for antibiotic resistance revealed
Tests of antibiotic resistance in cattle have revealed stark variation across thirteen European countries. The results, published today in BioMed Central's open-access journal Acta Veterinaria Scandinavica, show that major differences were apparent in the occurrence of resistance between countries and between the different antimicrobial agents tested.
Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States.
Infectious diseases experts applaud bill against 'bad bugs'
With methicillin-resistant Staphylococcus aureus (MRSA) infections, extensively drug-resistant tuberculosis, and other "bad bugs" routinely making headlines, infectious diseases physicians are applauding Sens. Sherrod Brown (D-OH) and Orrin Hatch (R-UT) for introducing in the Senate the Strategies To Address Antimicrobial Resistance (STAAR) Act.
Understanding, combating foodborne pathogens E. coli 0157 and salmonella
Understanding the ecology of two dangerous foodborne pathogens and devising ways to combat them is a big job. That's why Kansas State University has a team of seven researchers and six collaborators taking on E. coli 0157 and salmonella.
Infectious diseases experts applaud bill against 'bad bugs'
With extensively drug-resistant tuberculosis, life-threatening drug-resistant respiratory and skin infections, and other "bad bugs" routinely making headlines, infectious diseases physicians are applauding Rep. Jim Matheson (D-UT) and Rep. Michael Ferguson (R-NJ) for introducing H.R. 3697, the Strategies To Address Antimicrobial Resistance (STAAR) Act.
Scientists decipher mechanism behind antimicrobial 'hole punchers'
In the battle against bacteria, researchers have scored a direct hit. They have made a discovery that could shorten the road to new and more potent antibiotics.
GPs antibiotic prescribing practices are still contributing to resistance
GPs are still prescribing antibiotics for up to 80% of cases of sore throat, otitis media, upper respiratory tract infections, and sinusitis, despite the fact that official guidance warns against this practice.
Plants uptake antibiotics
Scientists at the University of Minnesota have been evaluating the impact of antibiotic feeding in livestock production on the environment.
Community-associated staph infections involving antibiotic-resistant bacteria increase
The incidence of antibiotic-resistant staph infections associated with being acquired in the community and not in health care institutions increased almost seven-fold in Chicago's Cook County Hospital system between 2000 and 2005.
Single dose of antibiotics before surgery sufficient to help prevent infection
A single dose of antibiotics prior to surgery appears to prevent infections occurring at the surgical site as effectively as a 24-hour dosing regimen, and with reduced antibiotic costs.
More Antimicrobial Resistance News Articles
| © 2008 BrightSurf.com |